Solventum Corporation

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 16, 2026, the Board of Directors of Solventum Corporation (the “Company”) appointed Neil Zieselman to serve as Senior Vice President, Controller and Chief Accounting Officer of the Company, effective as of August 10, 2026. Mr. Zieselman is replacing Mary Wilcox in this role in connection with her previously announced retirement and will report directly to Wayde McMillan, the Company’s Chief Financial Officer. Mr. Zieselman will function as the Company’s Principal Accounting Officer for Securities and Exchange Commission (“SEC”) reporting purposes. Mr. Zieselman, age 50, joins the Company from Surgery Partners, Inc., where he has served as its Senior Vice President, Corporate Finance and Controller since May 2022. Prior to Surgery Partners, Inc., Mr. Zieselman served Stryker Corporation as its Vice President, Finance Operations from April 2021 to May 2022, Senior Director, Finance Transformation from August 2019 to April 2021 and Senior Director, Finance and Group Controller, Orthopaedics Group from January 2017 to August 2019. Prior to joining Stryker Corporation, Mr. Zieselman held accounting and finance leadership roles at Covanta Holding Corporation, including Vice President and Chief Accounting Officer, Cendant Corporation and Avaya Inc. Mr. Zieselman began his career as an auditor with PricewaterhouseCoopers LLP. Mr. Zieselman is a licensed CPA and graduated Summa Cum Laude with a Bachelors of Science degree in Accounting from Rider University. In connection with Mr. Zieselman’s appointment as Senior Vice President, Controller and Chief Accounting Officer, Mr. Zieselman’s compensation will consist of an annual base salary materially consistent with the scope of role and experience, and a target annual bonus of 50% of base salary, subject to employment on the applicable payment date. Mr. Zieselman will be eligible for an annual long-term incentive target award of $500,000. Mr. Zieselman will receive a cash sign-on bonus of $130,000 and an initial grant of $600,000 of restricted stock units, which will vest in three equal installments on the first three anniversaries of the grant date, subject to continued employment. Additionally, as a result of Mr. Zieselman’s appointment, he is eligible to participate in the Solventum Executive Severance Plan. For more information on the Solventum Executive Severance Plan, see the Current Report on Form 8-K filed with the SEC on May 27, 2026. The appointment of Mr. Zieselman was not pursuant to any agreement or understanding between him and any other person. There is no family relationship between Mr. Zieselman and any director or executive officer of the Company, and there are no transactions between Mr. Zieselman and the Company that are required to be reported under Item 404(a) of Regulation S-K.